Researchers have designed antibody-like receptor proteins that can bind to cytokines, possibly reducing the effects of the COVID-19 associated cytokine storm.
People with OCD have six times higher Immuno-moodulin (Imood) expression that those without the disorder. Blocking Imood with the aid of an antibody reduced OCD-like behaviors in mouse models within a couple of days following treatment.
Researchers are sifting through millions of antibodies produced by those who have recovered from COVID-19 to find which ones neutralize the virus. The team has already identified several antibodies that block coronavirus from interacting with its receptors.
Researchers have identified a fully human monoclonal antibody that prevents SARS-CoV-2, the virus that causes COVID-19, from infecting cultured cells. The antibody binds to a domain that is conserved in SARS-CoV-2, neutralizing the virus. The findings are an initial step towards developing a fully human antibody to prevent or treat coronavirus.
Recovered coronavirus patients show a wide range of immune responses following the infection, with about half from a current study showing sustained antibodies two weeks later. Results indicate which parts of the virus are most effective at triggering the immune responses.
Using computational methods, researchers created artificial proteins that triggered immune responses and produced infection specific antibodies. The findings indicate it will be possible to design vaccines that contain artificial antibodies, expediting the process of vaccine development.
S309, a neutralizing antibody first identified in blood samples from a patient who recovered from SARS in 2003, shows promise for the treatment of COVID-19.
While the amount of antibodies generated varies widely in patients who have recovered from coronavirus, most people generate at least some antibodies which are intrinsically capable of neutralizing the SARS-CoV-2 virus.
Researchers have isolated a set of antibodies from a llama which show promise for the treatment of COVID-19. The NIH-CoVnB-112 nanoantibody bound to ACE2 receptors up to ten times stronger than other lab-produced antibodies. The nanoantibody stuck directly to the ACE2 receptor binding portion of the SARS_CoV-2 spike protein. The protein could be effective in preventing coronavirus infection.